Keywords
Children
Pediatrics
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To gather recent information on brain tumors in pediatric age, bringing data on the most common types, discoveries about their development, consequences on quality of life, treatments, and diagnoses. Bibliographic review: Pediatric malignant tumors generally affect the cells of the hematopoietic system and the supporting tissues, which is explained by the fact that they are predominantly embryonic in nature, originating from undifferentiated cells, unlike what occurs with cancer in adults, which usually affects the epithelial cells. Malignant brain tumors occupy between first and third place in cancer incidence and mortality in children, depending on the country, and are the main cause of cancer death in this population. Among the most common brain tumors in the pediatric population are medulloblastoma and glioma. The use of FET-PET seems to be more accurate in differentiating and evaluating brain tumors in pediatric age than MRI and should be indicated when there are doubts in the identification of lesions. Final considerations: Little is known about the etiology of childhood brain tumor. Better targeting for the treatment of these types of cancer is also needed, which has been developed through epigenetic therapies.
References
ACHIHA T, et al. Activated leukocyte cell adhesion molecule expression correlates with the WNT subgroup in medulloblastoma and is involved in regulating tumor cell proliferation and invasion. PLoS One, 2020; 15(12): e0243272.
BENAGE SJ, PICKA MCM. A espectroscopia por ressonância magnética no diagnóstico de tumores encefálicos pediátricos. Tekhne e Logos, 2016; 7(3): 100-113.
BORGENVIK A, et al. Targeting MYCN in Molecularly Defined Malignant Brain Tumors. Frontiers in Oncology, 2021; 28; 10:626751.
CARVALHO WMO, et al. Aspectos epidemiológicos do câncer infantojuvenil em uma capital do nordeste brasileiro. Revista Eletrônica Acervo Saúde (REAS), 2020; 2(11): e4045.
FANGUSARO J, et al. A Phase 2 trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: A Pediatric Brain Tumor Consortium Study. Neuro Oncology, 2021; 25: noab047.
FISHER MJ, et al. Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). Acta Neuropathologica, 2021; 14.
GROSSE F, et al. Benefit of static FET PET in pretreated pediatric brain tumor patients with equivocal conventional MRI results. Klinische Padiatrie, 2021; 17.
JEAN-QUARTIER C, et al. Mutation-based clustering and classification analysis reveals distinctive age groups and age-related biomarkers for glioma. BMC Medical Informatics and Decision Making, 2021; 21(1): 77.
MUOIO B, et al. Recent developments of 18F-FET PET in neuro-oncology. Current Medicinal Chemistry, 2018; 25(26): 3061-3073.
NGUYEN TMK, et al. Proportion of children with cancer that have an indication for genetic counseling and testing based on the cancer type irrespective of other features. Familial Cancer, 2021; 26.
SHAHAB S, FANGUSARO J. Neonatal central nervous system tumors. Clinics in Perinatology, 2021; 48(1): 35-51.
TOMOMASA R, et al. Ependymoma-like tumor with mesenchymal differentiation harboring C11orf95-NCOA1/2 or -RELA fusion: A hitherto unclassified tumor related to ependymoma. Brain Pathology, 2021; 12: e12943.
VAN SCHAIK J, et al. High Prevalence of Weight Gain in Childhood Brain Tumor Survivors and Its Association With Hypothalamic-Pituitary Dysfunction. Journal of Clinical Oncology, 2021; 23: JCO2001765.
WANG J, et al. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137. Cell Death & Disease, 2020; 11(12): 1029.
WEN J, HADDEN MK. Medulloblastoma drugs in development: Current leads, trials and drawbacks. European Journal of Medicinal Chemistry, 2021; 215: 113268.
YE Z, et al. Diffusion histology imaging differentiates distinct pediatric brain tumor histology. Scientific Reports, 2021; 11(1): 4749.